A few months back, when Takeda caused jaws to drop with its eye-watering $4 billion cash upfront for a mid-stage TYK2 drug from Nimbus, it had already taken a deep dive on the solid Phase IIb data Nimbus had assembled from its dose-ranging study in psoriasis. Now, it’s rolling that data out, eager…
#tyk2 #nimbus #bristolmyerssquibb #takeda #unlock
Continue reading...